The efficacy and safety of bimatoprost/timolol maleate, latanoprost/timolol maleate, and travoprost/timolol maleate fixed combinations on 24-h IOP
Küçük Resim Yok
Tarih
2018
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Springer
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Purpose To evaluate the effect of bimatoprost/timolol maleate fixed combination (BTFC), latanoprost/timolol maleate fixed combination (LTFC), and travoprost/timolol maleate fixed combination (TTFC) on 24-h intraocular pressure (IOP) in patients with open-angle glaucoma. Methods This prospective, observer-masked, randomized study included 50 patients with primary open-angle glaucoma. All patients were using hypotensive lipids and timolol maleate fixed combination treatment for >= 4 weeks and had an IOP ae 21 mmHg. Group 1 (n = 18) received BTFC, group 2 (n = 14) received LTFC, and group 3 (n = 18) received TTFC. All patients were hospitalized, and IOP was monitored for 24-h (10:00, 14:00, 18:00, 22:00, 02:00, and 06:00). Mean diurnal IOP variation measurements were taken between 06:00 and 18:00, and mean nocturnal IOP variation measurements were taken between 22:00 and 02:00. Mean IOP and IOP variation in the three groups were compared. Results Mean 24-h IOP did not differ significantly between the three groups (group 1: 14.6 +/- 2.9 mmHg; group 2: 14.1 +/- 3.7 mmHg and group 3: 15.8 +/- 2.0 mmHg; P > 0.05). Mean diurnal IOP variation was 4.6 +/- 2.3 mmHg in group 1, 5.8 +/- 2.4 mmHg in group 2, and 4.3 +/- 1.7 mmHg in group 3, and mean nocturnal IOP variation was 3.2 +/- 2.8 mmHg in group 1, 2.9 +/- 1.9 mmHg in group 2, and 3.0 +/- 1.6 mmHg group 3. There were not any significant differences in diurnal or nocturnal IOP variation between the three groups (P < 0.05). Conclusion All three fixed combinations effectively controlled IOP for 24-h and had a similar effect on diurnal and nocturnal IOP variations.
Açıklama
11th Congress of the European-Glaucoma-Society (EGS) -- JUN 07-14, 2014 -- Nice, FRANCE
Anahtar Kelimeler
Bimatoprost/timolol maleate, Latanoprost/timolol maleate, And travoprost/timolol maleate, 24-h IOP
Kaynak
International Ophthalmology
WoS Q Değeri
Q3
Scopus Q Değeri
Q2
Cilt
38
Sayı
4
